Edesa Biotech, Inc. (EDSA) Cash Flow Statement
Where EDSA’s cash came from and went, FY2025
September 30, 2025 · U.S. dollars- Cash from operations
- −$7.3M
- Capital expenditures
- $0
- Free cash flow
- −$7.3M
- Returned to shareholders
- —
- Change in cash
- $9.8M cash at year-end $10.8M
Cash from operations
−$7.3M
Shares issued
+$17.6M
Other financing
−$567,556
Currency & other
+$46,216
Change in cash
$9.8M
Drawn to scale: where the cash came from and how it was used. Hover for values.
EDSA operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
EDSA cash flow trends, FY2016–FY2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$4.5MFY2016 | −$7.3MFY2025 | — | |
| Capital expenditures | $402,271FY2016 | $0FY2025 | −100.0% | |
| Free cash flow | −$4.9MFY2016 | −$7.3MFY2025 | — | |
| Free cash flow margin | −385.9%FY2016 | −2,734,215.4%FY2021 | −2,733,829.5 pts | |
| Stock-based compensation | $259,379FY2016 | $729,642FY2025 | +12.2%/yr | |
| Share buybacks (net) | $0FY2016 | $0FY2018 | — | |
| Capex / revenue | 31.6%FY2016 | 1,229.2%FY2021 | +1,197.6 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
EDSA cash flow by activity
OperatingInvestingFinancingChange in cash
EDSA net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
EDSA cash flow statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$7.2M | −$6.2M | −$8.4M | −$17.5M | −$13.3M | −$6.4M | −$2.8M | −$5.0M | −$5.0M | −$5.0M |
| Depreciation & amortization | $119,273 | $186,049 | $183,471 | $118,188 | $118,788 | $57,563 | $4,779 | $188,372 | $179,322 | $149,565 |
| Stock-based compensation | $729,642 | $537,492 | $1.2M | $2.3M | $3.2M | $598,359 | $46,508 | $154,313 | $115,546 | $259,379 |
| Change in working capital | −$985,654 | $571,065 | $308,004 | $2.9M | −$3.6M | $721,968 | −$2.1M | $13,042 | $198,159 | −$23,649 |
| Other non-cash items | $0 | −$14,766 | $0 | $0 | $0 | $0 | −$11,434 | $67,717 | −$162,028 | $135,156 |
| Cash from operating activities | −$7.3M | −$4.9M | −$6.6M | −$12.3M | −$13.7M | −$5.0M | −$4.8M | −$4.6M | −$4.7M | −$4.5M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | $0 | −$3 | −$5,656 | −$6,146 | −$34,339 | −$8,095 | −$382,810 | −$302,733 | −$402,271 |
| Investments (net) | — | — | $41 | −$5,656 | −$6,146 | $19,073 | $6.4M | −$4.5M | $1.7M | $557,411 |
| Acquisitions & other investing | — | — | — | $5,656 | $6,146 | $34,339 | $8,095 | $382,810 | $302,733 | $402,271 |
| Cash from investing activities | — | — | — | −$5,656 | −$6,146 | $19,073 | $6.4M | −$4.5M | $1.7M | $557,411 |
| Financing activities | ||||||||||
| Share repurchases & issuance (net) | — | — | — | — | — | — | — | $9.2M | — | $7.6M |
| Net borrowing (repayment) | $0 | −$29,532 | $0 | — | $0 | $29,748 | $29,748 | $29,748 | $442,843 | — |
| Shares issued | $17.6M | $729,387 | $4.3M | $12.0M | $12.7M | $4.4M | $0 | $4.5M | $0 | $0 |
| Other financing | −$567,556 | −$107,824 | $485,094 | −$328,059 | $1.5M | $2.7M | $7.1M | −$4.9M | −$436,932 | −$332,764 |
| Cash from financing activities | $17.0M | $592,031 | $4.8M | $11.6M | $14.2M | $7.1M | $7.1M | $8.8M | $5,911 | $7.3M |
| Summary | ||||||||||
| Net change in cash | $9.8M | −$4.3M | −$1.7M | −$748,340 | $625,564 | $2.2M | $1.7M | −$345,430 | −$2.8M | $3.5M |
| Cash at end of period | $10.8M | $1.0M | $5.4M | $7.1M | $7.8M | $7.2M | $5.0M | $4.2M | $4.6M | $7.4M |
| Free cash flow | −$7.3M | −$4.9M | −$6.6M | −$12.3M | −$13.7M | −$5.0M | −$4.9M | −$5.0M | −$5.0M | −$4.9M |
| Free cash flow margin | — | — | — | — | −2,734,215.4% | −1,527.0% | −1,181.4% | −2,359.4% | −2,191.3% | −385.9% |
| Capex / revenue | — | — | — | — | 1,229.2% | 10.4% | 2.0% | 180.7% | 132.6% | 31.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$6.0M | −$4.2M | −$1.6M | −$2.2M | −$1.7M | −$1.6M | −$1.6M | −$962,051 | −$1.7M | −$1.9M | −$1.7M | −$1.7M |
| Depreciation & amortization | $25,644 | $25,872 | $25,460 | $25,868 | $25,787 | $24,509 | $43,109 | $44,206 | $51,415 | $45,397 | $45,031 | $45,970 |
| Stock-based compensation | −$147,836 | $66,653 | $81,183 | $404,425 | $177,381 | $66,653 | $81,183 | $93,933 | $100,000 | $100 | $184,357 | $517 |
| Change in working capital | −$1.4M | $1.7M | −$264,987 | $77,071 | $107,032 | −$884,012 | −$24,242 | −$143,127 | $650,812 | $21,159 | $42,535 | −$312,486 |
| Other non-cash items | $4.5M | $371,832 | −$311,737 | −$44,549 | −$311,734 | $0 | $0 | $0 | $9,506 | $119,299 | $0 | $508,687 |
| Cash from operating activities | −$3.0M | −$2.1M | −$2.1M | −$1.8M | −$1.8M | −$2.4M | −$1.5M | −$967,039 | −$856,479 | −$1.7M | −$1.4M | −$1.5M |
| Investing activities | ||||||||||||
| Capital expenditures | −$7 | −$3 | −$4 | −$3 | $0 | −$3 | −$3 | $0 | −$4 | −$4 | $0 | −$5 |
| Investments (net) | — | — | — | — | — | — | — | — | — | — | $0 | $0 |
| Financing activities | ||||||||||||
| Net borrowing (repayment) | — | — | — | $0 | $0 | — | — | $0 | $0 | — | — | — |
| Shares issued | $3.5M | $0 | $3.5M | $220,501 | $0 | $15.2M | $2.2M | $0 | $138,391 | $275,795 | $315,201 | $483,772 |
| Other financing | −$81,114 | $19,080 | −$142,406 | $23,883 | $216,924 | −$437,503 | −$96,035 | −$31,435 | −$32,366 | −$61,529 | −$9,459 | −$68,118 |
| Cash from financing activities | $3.4M | $19,080 | $3.4M | $244,384 | $216,924 | $14.8M | $2.1M | −$31,435 | $106,025 | $214,266 | $305,742 | $415,654 |
| Summary | ||||||||||||
| Net change in cash | $328,837 | −$2.0M | $1.3M | −$1.6M | −$1.5M | $12.3M | $526,182 | −$1.0M | −$758,747 | −$1.5M | −$1.1M | −$1.1M |
| Cash at end of period | $10.3M | $10.0M | $12.1M | $10.8M | $12.4M | $13.9M | $1.6M | $1.0M | $2.0M | $2.8M | $4.3M | $5.4M |
| Free cash flow | −$3.0M | −$2.1M | −$2.1M | −$1.8M | −$1.8M | −$2.4M | −$1.5M | −$967,039 | −$856,479 | −$1.7M | −$1.4M | −$1.5M |
| Free cash flow margin | — | −4,028.1% | — | — | — | — | — | — | — | — | — | — |
| Capex / revenue | — | 0.0% | — | — | — | — | — | — | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
EDSA cash generation
In fiscal 2025 (ended September 30, 2025), Edesa Biotech generated -$7.3 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$7.3 million. Cash and equivalents rose by $9.8 million over the year.
Related: EDSA income statement, EDSA balance sheet. See the EDSA stock overview for the latest quote and news.
EDSA cash flow FAQ
What is Edesa Biotech's free cash flow?
Edesa Biotech's free cash flow was -$7.3 million in fiscal 2025: -$7.3 million of operating cash flow minus $0 of capital expenditures It was -$4.9 million a year earlier..
How much cash does Edesa Biotech generate from operations?
Edesa Biotech generated -$7.3 million of cash from operating activities in fiscal 2025.